Arbutus Biopharma Corp Stock Performance
| ABUS Stock | USD 3.33 0.03 0.91% |
The firm shows a Beta (market volatility) of -0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Arbutus Biopharma are expected to decrease at a much lower rate. During the bear market, Arbutus Biopharma is likely to outperform the market. At this point, Arbutus Biopharma Corp has a negative expected return of -0.22%. Please make sure to confirm Arbutus Biopharma's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arbutus Biopharma Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Arbutus Biopharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.91 | Five Day Return 0.6 | Year To Date Return 1.22 | Ten Year Return (86.58) | All Time Return (47.14) |
Last Split Factor 1:5 | Last Split Date 2010-11-04 |
1 | Arbutus Biopharma Corp Q3 2024 Earnings Call Highlights Promising Clinical Trials and ... | 11/07/2024 |
2 | Arbutus Biopharma Co. Position Trimmed by Verus Capital Partners LLC | 11/14/2024 |
3 | HC Wainwright Reiterates Buy Rating for Arbutus Biopharma - MarketBeat | 11/18/2024 |
4 | Arbutus to Participate in H.C Wainwright Home Virtual Fireside Chat | 11/26/2024 |
5 | Arbutus Biopharma Co. Short Interest Update - MarketBeat | 12/02/2024 |
6 | Investor urges Bucks County firm Arbutus to seek partner over sale of stock | 12/05/2024 |
7 | Heres Why Arbutus Surged in Q3 | 12/06/2024 |
8 | Arbutus Biopharmas SWOT analysis hepatitis B focus drives stock potential | 12/16/2024 |
9 | Arbutus Biopharma Sees Large Volume Increase - Should You Buy - MarketBeat | 01/07/2025 |
10 | Jim Cramer onArbutus Biopharma Corporation It Loses Money | 01/16/2025 |
| Begin Period Cash Flow | 30.8 M |
Arbutus |
Arbutus Biopharma Relative Risk vs. Return Landscape
If you would invest 387.00 in Arbutus Biopharma Corp on November 3, 2024 and sell it today you would lose (54.00) from holding Arbutus Biopharma Corp or give up 13.95% of portfolio value over 90 days. Arbutus Biopharma Corp is currently does not generate positive expected returns and assumes 2.6336% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Arbutus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arbutus Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arbutus Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arbutus Biopharma Corp, and traders can use it to determine the average amount a Arbutus Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0821
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABUS |
Estimated Market Risk
| 2.63 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arbutus Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arbutus Biopharma by adding Arbutus Biopharma to a well-diversified portfolio.
Arbutus Biopharma Fundamentals Growth
Arbutus Stock prices reflect investors' perceptions of the future prospects and financial health of Arbutus Biopharma, and Arbutus Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arbutus Stock performance.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 498.97 M | ||||
| Shares Outstanding | 189.49 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 5.85 X | ||||
| Price To Sales | 92.75 X | ||||
| Revenue | 18.14 M | ||||
| Gross Profit | (56.05 M) | ||||
| EBITDA | (70.99 M) | ||||
| Net Income | (72.85 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 8.72 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (85.94 M) | ||||
| Earnings Per Share | (0.43) X | ||||
| Market Capitalization | 625.32 M | ||||
| Total Asset | 144.4 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 109.54 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
About Arbutus Biopharma Performance
Assessing Arbutus Biopharma's fundamental ratios provides investors with valuable insights into Arbutus Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arbutus Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (845.38) | (803.11) | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.79) | (0.75) |
Things to note about Arbutus Biopharma Corp performance evaluation
Checking the ongoing alerts about Arbutus Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arbutus Biopharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arbutus Biopharma generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 18.14 M. Net Loss for the year was (72.85 M) with loss before overhead, payroll, taxes, and interest of (56.05 M). | |
| Arbutus Biopharma Corp currently holds about 150.2 M in cash with (85.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0. | |
| Arbutus Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Jim Cramer onArbutus Biopharma Corporation It Loses Money |
- Analyzing Arbutus Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arbutus Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Arbutus Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arbutus Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arbutus Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arbutus Biopharma's stock. These opinions can provide insight into Arbutus Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.